natgillin/translations-raw huggingface dataset:
Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities. 
Bolnikom je treba svetovati, naj ne vozijo, ne upravljajo zapletenh strojev in ne sodelujejo pri drugih potencialno nevarnih dejavnostih, dokler ni znano, kako to zdravilo vpliva na njihovo zmožnost za takšne dejavnosti.
Tell your doctor if you have a history of any serious medical conditions, including liver or kidney disease. 
Zdravniku povejte, če ste v preteklosti imeli kakšne hujše zdravstvene težave, vključno z boleznijo jeter ali ledvic.
Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). 
Hemodializa učinkovito odstrani pregabalin iz plazme (50 % zdravila v 4 urah).
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription. 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept.
For three times a day take Pregabalin Mylan Pharma once in the morning, once in the afternoon and once in the evening, at about the same time each day. 
Pregabalin Mylan Pharma dvakrat na dan, ga vzemite enkrat zjutraj in enkrat zvečer, in sicer vsak dan ob približno istem času.
Pregabalin oral bioavailability is estimated to be ≥ 90% and is independent of dose. 
Ocenjena biološka uporabnost pregabalina po peroralni uporabi je ≥ 90 % in ni odvisna od odmerka.
In addition, pregabalin is effectively removed from plasma by haemodialysis (following a 4 hour haemodialysis treatment plasma pregabalin concentrations are reduced by approximately 50%). 
Poleg tega hemodializa učinkovito odstrani pregabalin iz plazme (po 4-urni hemodializi se koncentracija pregabalina v plazmi zmanjša za približno 50 %).
BID = Two divided doses * Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose + Supplementary dose is a single additional dose 
2-krat/dan = dva deljena odmerka * Celotni dnevni odmerek (mg/dan) je treba razdeliti, kot navaja odmerna shema, da dobimo mg/odmerek.
Adverse effects on male reproductive organs and sperm parameters were reversible and occurred only at exposures sufficiently in excess of therapeutic exposure or were associated with spontaneous degenerative processes in male reproductive organs in the rat. 
Neželeni učinki na moške spolne organe in na lastnosti sperme so bili reverzibilni in so se pojavili samo pri izpostavljenosti, ki je bila v zadostni meri večja od terapevtske izpostavljenosti ali pa so bili povezani s spontanim degenerativnim procesom v spolnih organih pri podganjih samcih.
Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy receiving anti-epileptic drugs and patients with chronic pain. 
Farmakokinetika pregabalina v stanju dinamičnega ravnovesja je podobna pri zdravih prostovoljcih, bolnikih z epilepsijo, ki dobivajo antiepileptična zdravila, in bolnikih s kroničnimi bolečinami.
• Decrease in white blood cell count 
• zmanjšanje števila belih krvničk
Hypersensitivity Angioedema, allergic reaction 
Redki preobčutljivost angioedem, alergična reakcija
No specific pharmacokinetic studies were carried out in patients with impaired liver function. 
Specifičnih farmakokinetičnih raziskav pri bolnikih z okvarjenim delovanjem jeter ni bilo.
Pregabalin clearance is directly proportional to creatinine clearance. 
Očistek pregabalina je neposredno sorazmeren očistku kreatinina.
The pregabalin clinical programme involved over 8900 patients exposed to pregabalin, of whom over 5600 were in double-blind placebo controlled trials. 
Klinični program pregabalina je zajel prek 8.900 bolnikov, izpostavljenih temu zdravilu; 5.600 od teh je bilo vključenih v dvojno slepa, s placebom nadzorovana preskušanja.
The symptoms of GAD are prolonged excessive anxiety and worry that are difficult to control. 
Simptoma te bolezni sta dolgotrajna in pretirano izražena tesnobnost in zaskrbljenost, ki ju bolnik le težko obvladuje.
Additional reactions reported from post-marketing experience are included in italics in the list below. 
Dodatni neželeni učinki, o katerih so poročali v obdobju trženja, so v spodnji preglednici navedeni v ležeči pisavi.
This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age. 
Zmanjšanje peroralnega očistka pregabalina je skladno z zmanjšanjem očistka kreatinina, ki je povezan z naraščajočo starostjo.
Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin. 
Zato plazemskih koncentracij pregabalina ni potrebno rutinsko nadzorovati.
The degree of dizziness, sleepiness and decreased concentration may be increased if Pregabalin Mylan Pharma is taken together with medicinal products containing: 
Omotica, zaspanost ali zmanjšanje sposobnosti koncentracije se lahko stopnjujejo, če zdravilo Pregabalin Mylan Pharma vzamemo skupaj z zdravili, ki vsebujejo:
Capsules shell Iron oxide yellow (E172) Titanium dioxide (E171) Erythrosine (E127) Gelatin 
Ovojnica kapsule rumeni železov oksid (E172) titanov dioksid (E171) eritrozin (E127) želatina natrijev lavrilsulfat
Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats. 
Dokazano je, da pregabalin pri podganah prehaja skozi placento in je prisoten v mleku doječih podgan.
These symptoms may occur more commonly or severely if you have been taking Pregabalin Mylan Pharma for a longer period of time. 
Ti znaki se lahko pojavljajo bolj pogosto in z večjo izrazitostjo, če ste zdravilo Pregabalin Mylan Pharma jemali daljši čas.
Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin misuse, abuse or dependence (development of tolerance, dose escalation, drug-seeking behaviour have been reported). 
Pri bolnikih z anamnezo zlorabe prepovedanih snovi je potrebna previdnost in jih je potrebno nadzirati glede možnih simptomov nepravilne uporabe, zlorabe ali odvisnosti od pregabalina (poročali so o razvoju tolerance, povečevanju odmerka in povpraševanju po zdravilu).
At therapeutic exposures, there was evidence of CNS clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight gain suppression). 
Pri izpostavljenosti terapevtskim odmerkom so bili opaženi klinični znaki prekomernega delovanja osrednjega živčnega sistema in bruksizma ter nekatere spremembe v rasti (prehodna supresija povečanja telesne mase).
Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may precipitate encephalopathy. 
Poročali so o primerih encefalopatije, predvsem pri bolnikih z osnovnimi stanji, ki lahko izzovejo encefalopatijo.
The pharmacokinetics of 150 mg pregabalin given every 12 hours (300 mg daily dose) was evaluated in 10 lactating women who were at least 12 weeks postpartum. 
Farmakokinetiko 150 mg pregabalina, z odmerjanjem na 12 ur (300 mg dnevno), so preučevali pri 10 doječih materah, pri katerih je od poroda minilo najmanj 12 tednov.
In vivo studies and population pharmacokinetic analysis Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. 
Raziskave in vivo in analiza populacijske farmakokinetike Skladno s tem v raziskavah in vivo niso ugotovili klinično pomembnih farmakokinetičnih interakcij med pregabalinom in fenitoinom, karbamazepinom, valprojsko kislino, lamotriginom, gabapentinom, lorazepamom, oksikodonom ali etanolom.
In prenatal/postnatal toxicity studies, pregabalin induced offspring developmental toxicity in rats at exposures >2 times the maximum recommended human exposure. 
V raziskavah prednatalne/ponatalne toksičnosti je pregabalin povzročil razvojno toksičnost za potomstvo podgan pri izpostavljenostih, ki so bile > 2-krat večje od največje priporočene izpostavljenosti pri človeku.
Maximum dose (mg/day) 
največji odmerek (mg/dan)
The other ingredients are: hydroxylpropylcellulose, maize starch, talc, gelatin, titanium dioxide (E171), sodium laurilsulfate, black ink (which contains shellac, black iron oxide (E172), macrogol, potassium hydroxide and concentrated ammonia solution), yellow iron oxide (E172) and erythrosine (E127). 
Druge sestavine zdravila so: hidroksipropilceluloza, koruzni škrob, smukec, želatina, titanov dioksid (E171), natrijev lavrilsulfat, črno črnilo (ki vsebuje šelak, črni železov oksid (E172), makrogol, kalijev hidroksid in koncentrirano raztopino amonijaka), rumeni železov oksid (E172) in eritrozin (E127).
In the post-marketing experience, visual adverse reactions have also been reported, including loss of vision, visual blurring or other changes of visual acuity, many of which were transient. 
V obdobju trženja so poročali tudi o neželenih učinkih na vid; vključno z izgubo vida, zamegljenostjo vida ali drugimi spremembami ostrine vida, med katerimi so bile mnoge prehodnega značaja.
Pregnancy There are no adequate data from the use of pregabalin in pregnant women. 
Nosečnost O uporabi pregabalina pri nosečnicah ni zadostnih podatkov.
Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of pregabalin. 
Klinična preskušanja kažejo, da spol nima klinično pomembnega vpliva na koncentracijo pregabalina v plazmi.
Generalised Anxiety Disorder 
Generalizirana anksiozna motnja
The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis (see sections 4.2, 5.1 and 5.2). 
Najpogostejši neželeni učinki, opaženi v 12-tedenski študiji zdravljenja s pregabalinom, so bili somnolenca, pireksija, okužba zgornjih dihal, zvečanje apetita, zvečanje telesne mase in nazofaringitis (glejte poglavja 4.2, 5.1 in 5.2).
Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicinal product. 
Zato je bolnikom treba svetovati, naj bodo previdni, dokler ni znano, kako zdravilo učinkuje na njih.
Pregabalin Mylan Pharma with food, drink and alcohol Pregabalin Mylan Pharma capsules may be taken with or without food. 
Zdravilo Pregabalin Mylan Pharma skupaj s hrano, pijačo in alkoholom Kapsule Pregabalin Mylan Pharma lahko jemljete s hrano ali brez nje.
Adjunctive Treatment 
Dodatno zdravljenje
These symptoms include swelling of the face, lips, tongue, and throat, as well as diffuse skin rash. 
Med takšnimi so oteklost obraza, ustnic, jezika in žrela ter razširjen izpuščaj po koži.
• Swelling of the body including extremities 
• otekanje telesa, vključno z udi
Withdrawal of concomitant anti-epileptic medicinal products There are insufficient data for the withdrawal of concomitant anti-epileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin. 
Ukinitev sočasno uporabljenih antiepileptičnih zdravil Ni zadostnih podatkov za ukinitev sočasno uporabljenih antiepileptičnih zdravil in prehod na monoterapijo s pregabalinom, ko je pri dodatnem zdravljenju s pregabalinom dosežen nadzor nad napadi.
Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of 8 week duration and a long-term relapse prevention study with a double blind relapse prevention phase of 6 months duration. 
Pregabalin so raziskovali v 6 kontroliranih preskušanjih, ki so trajala od 4 do 6 tednov, v študiji starejših bolnikov, ki je trajala 8 tednov, ter v dolgoročni študiji preprečevanja recidiva s 6-mesečno dvojno slepo fazo preprečevanja recidiva.
Results of a 12-week placebo-controlled study of 295 paediatric patients aged 4 to 16 years performed to evaluate the efficacy and safety of pregabalin as adjunctive therapy for the treatment of partial onset seizures and a 1 year open label safety study in 54 paediatric patients from 3 months to 16 years of age with epilepsy indicate that the adverse events of pyrexia and upper respiratory infections were observed more frequently than in adult studies of patients with epilepsy (see sections 4.2, 4.8 and 
Rezultati 12-tedenske s placebom nadzorovane študije pri 295 pediatričnih bolnikih, starih od 4 do 16 let, ki so jo izvedli za ovrednotenje učinkovitosti in varnosti pregabalina kot dodatne terapije za zdravljenje parcialnih napadov in enoletne odprte študije varnosti pri 54 pediatričnih bolnikih z epilepsijo, starih od 3 mesecev do 16 let, kažejo, da so opazili neželene učinke - pireksijo in okužbe zgornjih dihal - pogosteje kot v študijah pri odraslih z epilepsijo (glejte poglavja 4.2, 4.8 in 5.2).
The pregabalin safety profile observed in three paediatric studies in patients with partial seizures with or without secondary generalization (12-week efficacy and safety study in patients with partial onset seizures, n=295; (pharmacokinetic and tolerability study, n=65; and 1 year open label follow on safety study, n=54) was similar to that observed in the adult studies of patients with epilepsy. 
Varnostni profil pregabalina, opažen v treh študijah pri otrocih s parcialnimi napadi s sekundarno generalizacijo ali brez nje (12-tedenska študija učinkovitosti in varnosti pri bolnikih s parcialnimi napadi, n=295; študija farmakokinetike in prenašanja zdravila, n = 65 in enoletna odprta nadaljevalna študija varnosti, n = 54), je bil podoben tistemu v študijah pri odraslih z epilepsijo.
Your doctor will prescribe Pregabalin Mylan Pharma for you to help treat your epilepsy when your current treatment is not controlling your condition. 
Zdravnik bo predpisal zdravilo Pregabalin Mylan Pharma kot pomoč za zdravljenje epilepsije, če zdravila, ki jih trenutno uporabljate, bolezni ne obvladujejo.
In mice, no increased incidence of tumours was found at exposures similar to the mean human exposure, but an increased incidence of haemangiosarcoma was observed at higher exposures. 
Pri miših niso opazili povečane pojavnosti tumorjev pri izpostavljenosti, podobni tisti pri človeku, toda pri večji izpostavljenosti so opazili povečano pojavnost hemangiosarkoma.
Pregabalin is excreted into human milk (see section 5.2). 
Pregabalin se izloča v materino mleko (glejte poglavje 5.2).
Take your box or bottle of Pregabalin Mylan Pharma capsules with you. 
S seboj vzemite svojo škatlo ali plastenko kapsul Pregabalin Mylan Pharma.
Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance. 
Analiza populacijske farmakokinetike je pokazala, da peroralni antidiabetiki, diuretiki, insulin, fenobarbital, tiagabin in topiramat nimajo klinično pomembnih učinkov na očistek pregabalina.
Fertility There are no clinical data on the effects of pregabalin on female fertility. 
Plodnost Ni kliničnih podatkov o vplivu pregabalina na plodnost pri ženskah.
In repeated dose toxicity studies in rats and monkeys CNS effects were observed, including hypoactivity, hyperactivity and ataxia. 
V raziskavah toksičnosti pri ponavljajočih se odmerkih pri podganah in opicah so opažali učinke na osrednjem živčevju, vključno s hipoaktivnostjo, hiperaktivnostjo in ataksijo.
Epilepsy: Pregabalin Mylan Pharma is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults. 
Epilepsija: Zdravilo Pregabalin Mylan Pharma se uporablja za zdravljenje določene oblike epilepsije (parcialnih napadov s sekundarno generalizacijo ali brez nje) pri odraslih.
Treatment of pregabalin overdose should include general supportive measures and may include haemodialysis if necessary (see section 4.2 Table 1). 
Zdravljenje prevelikega odmerjanja pregabalina mora obsegati splošne podporne ukrepe in lahko vključuje hemodializo, če je potrebno (glejte poglavje 4.2, preglednico 1).
• Feeling of elation, confusion, disorientation, decrease in sexual interest, irritability 
• občutek vznesenosti, zmedenost, dezorientiranost, zmanjšanje zanimanja za spolnost,
However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption. 
Vendar jemanje pregabalina s hrano nima klinično pomembnega vpliva na delež absorpcije pregabalina.
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (<2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions. 
Ker se pregabalin pretežno izloča nespremenjen v urinu in se pri človeku zanemarljivo presnavlja (< 2 % odmerka se pojavi v urinu v obliki presnovkov), ne zavira presnove zdravil in vitro in ni vezan na beljakovine v plazmi.
If while taking Pregabalin Mylan Pharma you notice decreased urination, you should tell your doctor as stopping the medicine may improve this. 
Če med jemanjem zdravila Pregabalin Mylan Pharma zasledite zmanjšano izločanje urina, morate to povedati zdravniku, saj se lahko s prenehanjem jemanja zdravila stanje izboljša.
Pregabalin Mylan Pharma may be taken with or without food. 
Zdravilo Pregabalin Mylan Pharma se lahko jemlje s hrano ali brez nje.
Pregabalin Mylan Pharma should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor. 
Zdravila Pregabalin Mylan Pharma ne smete uporabljati med nosečnostjo ali v obdobju dojenja, razen če vam tako svetuje zdravnik.
• A small number of people being treated with anti-epileptics such as Pregabalin Mylan Pharma have had thoughts of harming or killing themselves. 
• Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Mylan Pharma, so se pojavile misli na samopoškodovanje ali samomor.
Effective contraception must be used by women of child-bearing potential. 
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijsko zaščito.
Pregabalin was excreted into breast milk with average steady-state concentrations approximately 76% of those in maternal plasma. 
Povprečna koncentracija v materino mleko izločenega pregabalina je v stanju dinamičnega ravnovesja znašala približno 76 % materine plazemske koncentracije.
• Hepatitis (inflammation of the liver). 
• hepatitis (vnetje jeter)
• Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, 
• motnje srčnega ritma, pospešen srčni utrip, nizek krvni tlak, visok krvni tlak, spremembe srčnega utripa, srčno popuščanje
Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. 
Pregabalin se iz sistemskega obtoka odstrani predvsem z izločanjem nespremenjenega zdravila skozi ledvice.
There have been post-marketing reports of congestive heart failure in some patients receiving pregabalin. 
V obdobju trženja so poročali o primerih kongestivnega srčnega popuščanja pri nekaterih bolnikih, ki so dobivali pregabalin.
Adverse reactions were usually mild to moderate in intensity. 
Neželeni učinki so bili ponavadi blagi do zmerni.
A reduction in seizure frequency was observed by Week 1. 
Že do konca prvega tedna so opazili zmanjšanje pogostnosti napadov.
There have been reports in the post-marketing experience of hypersensitivity reactions, including cases of angioedema. 
V obdobju trženja so poročali o preobčutljivostnih reakcijah, vključno z angioedemom.
As pregabalin clearance is directly proportional to creatinine clearance (see section 5.2), dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CLcr), as indicated in Table 1 determined using the following formula: 
Očistek pregabalina je neposredno sorazmeren očistku kreatinina (glejte poglavje 5.2), zato je treba pri bolnikih z okrnjenim delovanjem ledvic odmerek individualno prilagoditi glede na očistek kreatinina (OČkr), kot prikazuje preglednica 1, po naslednji formuli:
For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. 
Pri bolnikih na hemodializi je treba dnevni odmerek pregabalina prilagoditi delovanju ledvic.
After discontinuation of short-term and long-term treatment with pregabalin, withdrawal symptoms have been observed in some patients. 
Po prekinitvi kratkotrajnega in dolgotrajnega zdravljenja s pregabalinom so pri nekaterih bolnikih opazili odtegnitvene simptome.
Urinary incontinence, dysuria Renal failure, oliguria, urinary retention 
Redki urinska inkontinenca, dizurija odpoved ledvic, oligurija, retencija urina
Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. 
Glede na bolnikov odziv in prenašanje je mogoče odmerek čez 1 teden zvečati na 300 mg na dan.
Pregabalin clearance tends to decrease with increasing age. 
Očistek pregabalina se s starostjo praviloma zmanjšuje.
Discontinuation of pregabalin may resolve the reaction. 
Prenehanje njegove uporabe lahko reakcijo odpravi.
Diabetic patients 
Bolniki z diabetesom
Paediatric population Pregabalin pharmacokinetics were evaluated in paediatric patients with epilepsy (age groups: 1 to 23 months, 2 to 6 years, 7 to 11 years and 12 to 16 years) at dose levels of 2.5, 5, 10 and 15 mg/kg/day in a pharmacokinetic and tolerability study. 
Farmakokinetiko pregabalina so ocenili v študiji farmakokinetike in prenašanja pri pediatričnih bolnikih z epilepsijo (starostne skupine: od 1 do 23 mesecev, od 2 do 6 let, od 7 do 11 let in od 12 do 16 let) z odmerki 2,5; 5, 10 in 15 mg/kg/dan.
The percentage of subjects with at least a 50% reduction in partial onset seizures as compared to baseline was 40.6% of subjects treated with pregabalin 10 mg/kg/day (p=0.0068 versus placebo), 29.1% of subjects treated with pregabalin 2.5 mg/kg/day (p=0.2600 versus placebo) and 22.6% of those receiving placebo. 
Delež preskušancev z vsaj 50 % zmanjšanjem pogostnosti parcialnih napadov v primerjavi z izhodiščem je bil pri preskušancih, ki so prejemali pregabalin v odmerku 10 mg/kg/dan, 40,6 % (p = 0,0068 v primerjavi s placebom), pri preskušancih, ki so prejemali pregabalin v odmerku 2,5 mg/kg/dan, 29,1 % (p = 0,2600 v primerjavi s placebom) in pri tistih, ki so prejemali placebo, 22,6 %.
Dizziness, somnolence, loss of consciousness, confusion and mental impairment Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. 
Omotica, somnolenca, izguba zavesti, zmedenost in poslabšanje mentalnih sposobnosti Zdravljenje s pregabalinom je bilo povezano z omotico in somnolenco, ki lahko v starejši populaciji zveča pogostnost nezgodnih poškodb (padcev).
Pregabalin Mylan Pharma may have minor or moderate influence on the ability to drive and use machines. 
Zdravilo Pregabalin Mylan Pharma ima lahko blag ali zmeren vpliv na sposobnost vožnje in upravljanja strojev.
Continue taking Pregabalin Mylan Pharma until your doctor tells you to stop. 
Zdravilo Pregabalin Mylan Pharma jemljite, dokler vam zdravnik ne naroči, da nehajte.
• When Pregabalin Mylan Pharma is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g., constipation, blocked or paralysed bowel). 
• Ob sočasni uporabi zdravila Pregabalin Mylan Pharma z ostalimi zdravili, ki lahko povzročijo zaprtost (kot so nekatera zdravila proti bolečinam), obstaja možnost pojava prebavnih težav (npr. zaprtje, zaprto ali paralizirano črevo).
• Your doctor will tell you to take Pregabalin Mylan Pharma either twice or three times a day. 
• Zdravilo Pregabalin Mylan Pharma morate vzeti dvakrat ali trikrat na dan.
Neutropaenia 
razdražljivost
UNIQUE IDENTIFIER - 2D BARCODE <2D barcode carrying the unique identifier included.> 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.